Pharma shares trade firm; Laurus up 2%, Sun Pharma nears 52-week high

Shares of pharmaceutical companies were trading firm in an otherwise subdued market, with Nifty Pharma index gaining nearly 1 per cent on the National Stock Exchange (NSE) on Wednesday, on expectation of improved outlook.

At 09:33 am; Nifty Pharma index, the top gainer among sectoral indices, was up 0.81 per cent at 13,948.60, as compared to 0.15 per cent rise in the Nifty50 index. The pharma index hit a 52-week high of 14,938.25 on October 4, 2021. In past seven trading days, the index has rallied 5.8 per cent.

Strides Pharma Science, Laurus Labs, Cipla, Natco Pharma, Lupin, Aurobindo Pharma, Ipca Laboratories, Dr Reddy’s Laboratories, Sun Pharmaceutical Industries and Cadila Healthcare were up in the range of 1 per cent to 2 per cent on the NSE.

Sun Pharma, Cipla, Natco, Dr Reddy’s, Torrent Pharma, Aurobindo Pharma and Strides have launched a generic version of Molnupiravir in India post approval for emergency use authorisation from Drugs Controller General of India (DCGI).

According to total sales data from IMS, IPM grew by 12 per cent year on year (yoy) in November 2021 vs 10 per cent yoy in October 2021. On a MAT basis, IPM grew by 18.2 per cent, driven by volume growth (9 per cent), new product growth (4.9 per cent) and pricing growth (4.3 per cent).

Analyst at Emkay Global Financial Services believes that IPM growth is returning to normal levels as Covid cases have dropped and the monsoon season has ended. Barring any Covid related upside, we expect IPM to grow in mid-to-high teens for FY22, implying high single digit growth in the rest of the financial year, the brokerage said in pharma sector update.

Among the individual stocks, Sun Pharma was up 1 per cent to Rs 824.50 on the NSE in intra-day deal. The share price of drug maker is trading close to its 52-week high of Rs 851 hit on October 18, 2021. The company also plans to set-up a end-to-end manufacturing unit in Andhra Pradesh.

Emkay maintains a ‘Hold’ rating on the stock as the brokerage firm said it believe the current valuations limit the upside potential in view of near-term headwinds such as potential increase in R&D expense, reversal of Covid and seasonal product sales in India and increase in S&M costs.

Sun Pharma’s Q2FY22 operational performance was better than brokerages estimates with growth in multiple segments moderated by decline in API sales.

That said higher contribution from specialty and strong domestic franchise is likely to change the product mix towards more remunerative businesses by FY22. This would have positive implications for margins also as we expect faster absorption of frontloaded costs on the specialty front, ICICI Securities said in Q2 results update.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor